Will Novartis's data manipulation damage relations with regulators?

Regulators rely on data. Before they’ll even consider allowing a new drug, crop protection agent or other chemical product onto the market, they need to see a truckload of it (quite literally – before electronic submissions, the boxes full of paperwork supporting a new drug application could easily fill a small lorry). But what if it turns out that the data is compromised?